ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Everolimus

Also written as “everolimus”, “RAD001” and “Everolimus (RAD001)”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Renal Cell · Tuberous Sclerosis · Carcinoma, Non-Small-Cell Lung · Neuroendocrine Tumors, led by 4 companies.

Drug pageEverolimus: every studyAll 618 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 8, 2005125 company-led studies, 2 open or runningNext primary completion: Feb 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only1201 open or runningphase 4since Sep 8, 2005Oct 6, 2004Feb 26, 2027phase 3 · NCT02962414
Chong Kun Dang Pharmaceutical21 open or runningphase 4since Apr 29, 2021Apr 29, 2021Dec 2030phase 4 · NCT06942156
iOMEDICOits history only20 open or runningphase 4since Dec 23, 2010Dec 23, 2010none ahead
Chiesi Farmaceuticiits history only10 open or runningphase 2since Oct 28, 2016Oct 28, 2016none ahead

Also a collaborator on its studies: Merck, Pfizer, Cromsource and Roche Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Chong Kun Dang Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 29, 2021First study: phase 4 study in Liver TransplantFirst studyNCT04867720 · 112 enrolled · Korea, Republic of
  2. Apr 11, 2025Phase 4 study in Heart TransplantNCT06942156 · 140 planned · Korea, Republic of

Ahead

  1. Dec 2030Primary completion: phase 4 study in Heart TransplantNCT06942156

TargetBeta

FKBP1A →read by rule
“FK506-binding protein 1A inhibitor”ChEMBL 37, by rule

Other programs on FKBP1A

ProgramCompanyFurthest phaseStudies
TacrolimusruleAstellas Pharmaphase 4182

Studies

All 2 Chong Kun Dang Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06942156Heart Transplant · Korea, Republic of4Not yet recruitingDec 2030140
NCT04867720Liver Transplant · Korea, Republic of4UNKNOWNOct 10, 2022112

How it is read

Names in the registry

  • “Everolimus”, 64 entries
  • “everolimus”, 16 entries
  • “RAD001”, 16 entries
  • “Everolimus (RAD001)”, 15 entries
  • “Everolimus (reduced tacrolimus)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.